Daily non-political popular news in brief.
Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW
05-22-2007 · EurekAlert!A long-term phase III, open-label 12-14 month extension study presented at the British Society of Gastroenterology meeting in Glasgow, Scotland, in March 2007 showed Shire plc's LIALDA is well-tolerated in mild-to-moderate UC patients. Today, secondary endpoints of study 303 were presented as post-hoc analyses at Digestive Disease Week.
Read more »
Keywords: ulcerative, colitis, remission, rates, long-term, safety, study, lialda, presented, ddw, coliti, rate, long, term
« Previous | Next »
Similar news on "Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW":
- New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10-15-2007 · EurekAlert!
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
Similar news · Read more »
- Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
10-23-2006 · EurekAlert!
Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
Similar news · Read more »
- Long-term ulcerative colitis study shows Remicade responders maintained improvement
05-23-2007 · EurekAlert!
Findings presented today at Digestive Disease Week 2007, from long-term extensions of the ACT trials show that subjects with moderately to severely active ulcerative colitis who had responded to REMICADE in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
Similar news · Read more »
- Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis
06-13-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced the presentation of additional data that showed that the safety profile of Enbrel was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis who completed up to eight years of therapy. The study results will be presented at the European League Against Rheumatism Annual Congress, an international rheumatology meeting, in Barcelona, Spain.
Similar news · Read more »
- Long-term 12-month safety data on ADHD patch DAYTRANA
10-25-2007 · EurekAlert!
Shire plc announced that DAYTRANA (methylphenidate transdermal system), the ADHD patch, provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years, according to data from a 12-month study presented today at a major scientific and educational meeting of child and adolescent psychiatrists.
Similar news · Read more »
- LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
10-17-2007 · EurekAlert!
According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery system where the majority of the drug's active ingredient, 5-aminosalicyclic acid, is released over a prolonged period in the simulated colon. The colon is the site of inflammation in ulcerative colitis.
Similar news · Read more »
- LIALDA demonstrates prolonged release of mesalamine
10-17-2007 · EurekAlert!
According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery system where the majority of the drug's active ingredient, 5-aminosalicyclic acid, is released over a prolonged period in the simulated colon. The colon is the site of inflammation in ulcerative colitis.
Similar news · Read more »
- LIALDA (TM) demonstrates prolonged release of mesalamine
10-17-2007 · EurekAlert!
According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery system where the majority of the drug's active ingredient, 5-aminosalicyclic acid, is released over a prolonged period in the simulated colon. The colon is the site of inflammation in ulcerative colitis.
Similar news · Read more »
- Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
10-25-2007 · EurekAlert!
Although many drugs have been used in the treatment of inflammatory bowel disease, none have yet been shown to modify the natural history of the diseases or to maintain a stable remission over time. The introduction of biological agents in the therapeutic armamentarium for Crohn's disease and ulcerative colitis has significantly changed the treatment strategies and outcomes of patients. Infliximab scheduled treatment has proven to be an effective strategy in IBD patients for long-term maintenance of clinical remission.
Similar news · Read more »
- Novel platelet therapy may reduce PCI complications
03-24-2007 · EurekAlert!
Despite the availability of numerous antithrombotic therapies, adverse events following percutaneous coronary intervention such as late-stent thrombosis are still a concern for cardiologists, and there's a need for medications that can minimize the risk of these complications but also manage the rate of bleeding. A study presented today at the American College of Cardiology's Innovation in Intervention: i2 Summit evaluates the safety and efficacy of a novel oral thrombin receptor antagonist in reducing PCI complications.
Similar news · Read more »
